Achieve Life Sciences (ACHV) Projected to Release Quarterly Earnings on Thursday

Key Points

• Achieve Life Sciences is expected to report Q3 2026 results before market open on November 5. Analysts project a loss of $0.20 per share and revenue of $10.65 million.
• The company reported Q2 EPS of ($0.80), substantially below the consensus estimate of ($0.16). Analysts expect full-year EPS of ($0.92) and next-year EPS of ($0.57).
• ACHV shares opened at $6.85, while analysts maintain a consensus “Buy” rating and a $15.50 price target; recent targets include $18.00 from Stifel and $13.00 from Morgan Stanley.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) is expected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $10.65 million for the quarter. Investors are encouraged to explore the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.64). On average, analysts expect Achieve Life Sciences to post ($0.92) EPS for the current fiscal year and ($0.57) EPS for the next fiscal year.

Achieve Life Sciences Stock Performance

Shares of ACHV stock opened at $6.85 on Thursday. Achieve Life Sciences has a 12-month low of $2.62 and a 12-month high of $8.64. The company has a debt-to-equity ratio of 0.87, a current ratio of 0.95 and a quick ratio of 0.95. The firm has a market capitalization of $704.88 million, a price-to-earnings ratio of -4.42 and a beta of 2.30. The business has a 50 day simple moving average of $7.50 and a 200 day simple moving average of $5.64.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Stifel Nicolaus set a $18.00 price target on Achieve Life Sciences and gave the stock a "buy" rating in a research report on Tuesday, September 29th. Weiss Ratings reissued a "sell (d-)" rating on shares of Achieve Life Sciences in a report on Wednesday, August 19th. Wall Street Zen lowered Achieve Life Sciences from a "hold" rating to a "strong sell" rating in a report on Saturday, August 15th. UBS Group restated a "buy" rating on shares of Achieve Life Sciences in a research note on Wednesday, August 12th. Finally, Morgan Stanley began coverage on shares of Achieve Life Sciences in a research note on Thursday, August 13th. They set an "overweight" rating and a $13.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Achieve Life Sciences currently has an average rating of "Buy" and a consensus target price of $15.50.

Insider Activity

In related news, Director Richard Stewart sold 20,626 shares of the firm's stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $8.49, for a total transaction of $175,114.74. Following the transaction, the director owned 208,249 shares in the company, valued at $1,768,034.01. This trade represents a 9.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.80% of the stock is owned by company insiders.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cytisinicline, a therapy designed to help adults quit smoking and overcome nicotine addiction. Cytisinicline is an oral, plant-based small molecule that partially activates nicotinic acetylcholine receptors, with the goal of reducing nicotine cravings and withdrawal symptoms.

The company has evaluated cytisinicline in clinical studies involving adults who smoke cigarettes, including trials assessing smoking cessation and cessation of electronic cigarette use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.